Medications for Carcinoid Tumor
5 results
I 123 mibg (i 123 mibg)
(i 123 MIBG)AnazaoHealth Corporation
Usage: Iobenguane (I-123 MIBG) is indicated for diagnostic imaging of adrenomedullary disorders, neuroendocrine tumors, pheochromocytomas, paragangliomas, neuroblastomas, carcinoid tumors, and medullary thyroid carcinoma. It assists in the evaluation, localization, and confirmation of these conditions, particularly when other tests yield unclear results.
Octreotide acetate (octreotide acetate)
(Octreotide acetate)Wockhardt Limited
Usage: Octreotide acetate is indicated for treating acromegaly in patients who have not responded adequately to surgery or other treatments, as well as for managing severe diarrhea and flushing in metastatic carcinoid tumors and profuse watery diarrhea in VIP-secreting tumors. It does not affect tumor size or growth.
Octreotide acetate (octreotide acetate)
(octreotide acetate)Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Usage: Octreotide acetate injection is indicated for reducing growth hormone and IGF-1 levels in acromegaly patients not responsive to other treatments, and for managing severe diarrhea and flushing in metastatic carcinoid tumors and watery diarrhea in VIPoma-associated tumors. Limitations exist regarding tumor size reduction and clinical improvement.
Octreotide acetate (octreotide acetate)
(octreotide acetate)Mylan Institutional LLC
Usage: Octreotide acetate injection is used to reduce growth hormone and IGF-1 levels in acromegaly patients who have not responded to other treatments. It also treats severe diarrhea and flushing from metastatic carcinoid tumors and profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas).
Octreotide acetate (octreotide acetate)
(Octreotide Acetate)Meitheal Pharmaceuticals, Inc.
Usage: Octreotide Acetate Injection is indicated for managing acromegaly in patients unresponsive to other treatments, treating severe diarrhea and flushing from metastatic carcinoid tumors, and addressing profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas). Clinical trials did not confirm its impact on tumor size or growth rate.